Open AccessThrombospondin-1 Expression in Bladder Cancer: Association With p53 Alterations, Tumor Angiogenesis, and Tumor Progression
Author(s) -
Gary D. Grossfeld,
David A. Ginsberg,
John P. Stein,
Bernard H. Bochner,
David Esrig,
Peter W. Nichols,
C R Taylor,
Richard J. Côté,
Susan Groshen,
Matthew D. Dunn,
Donald G. Skinner
Publication year - 1997
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/89.3.219
Subject(s) - angiogenesis , cystectomy , immunohistochemistry , bladder cancer , thrombospondin , neovascularization , thrombospondin 1 , medicine , metastasis , pathology , lymph node , microvessel , cancer research , tumor progression , cancer , metalloproteinase , matrix metalloproteinase
Thrombospondin-1 (TSP) is a 430-kd glycoprotein that is an important component of the extracellular matrix and is known to be a potent inhibitor of angiogenesis (i.e., formation of new blood vessels) both in vitro and in vivo. Several reports suggest that TSP possesses tumor suppressor function, possibly through its ability to inhibit tumor neovascularization. It has recently been shown that TSP expression is enhanced by the product of the p53 gene (also known as TP53).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom